Navigation Links
Confirmation of nitisinone efficacy for life-threatening liver disease
Date:10/31/2012

This release is available in French.

A consortium of Quebec researchers coordinated by the Medical Genetics Service of the Sainte-Justine UHC has just published the findings of a 25-year study on the treatment of tyrosinemia, a life-threatening liver disease of genetic origin, which is screened at birth in the province of Quebec, where it is much more frequent than anywhere else in the world. "After five years of treatment, no trace of the disease can be detected in the liver of newborns who were treated with nitisinone starting from the first month of life," states Dr. Grant Mitchell of the Sainte-Justine UHC and the University of Montreal, who is the senior author of a study published in Molecular Genetics and Metabolism in September 2012.

Due to a genetic mutation, tyrosine, an amino acid found in the diet, is not properly metabolized in the liver of children with tyrosinemia. Toxic compounds can therefore build up in the liver and trigger various complications such as liver cirrhosis and liver cancer, which most often require a liver transplant to ensure patient survival. The drug nitisinone produces spectacular results, since it lowers the level of toxins by modifying the way tyrosine is metabolized. If treatment is undertaken in the first month of a child's life and complied to, impaired liver function becomes normal again.

Forty years ago, 90 % of children with tyrosinemia died before ever reaching the age of two. The study shows that today, they can enjoy normal health for at least 18 years and possibly even for the rest of their lives. In Quebec, screening at birth has been performed since 1970 and nitisinone treatment has been available since 1994. The situation is different elsewhere in the world, where in most countries neonatal screening for tyrosinemia is not available.

In fact, outside Quebec, children are diagnosed with tyrosinemia only when they show up at the hospital with severe complications, usually when they are already a few months old. For these children, the study's findings are critical. "The treatment also helps children with a late diagnosis, because it prevents acute complications, notably the need for a liver transplant," explains Dr. Mitchell.

The Quebec group's findings erase all doubt about the efficacy of nitisinone treatment and the benefits of early tyrosinemia screening. The researchers hope that their conclusions will be quickly exported and adopted so children elsewhere in the world can also benefit from this rapid and optimal treatment.

Around the world, one person in 100,000 is afflicted with tyrosinemia. In Quebec, a genetic founder effect pushes this proportion up to one person in 16,000 and even one in 1,846 in the Saguenay region. According to Dr. Guy Parizeault, the pediatrician at the Chicoutimi Health and Social Service Center (CSSS) who took over from the study's first author, Dr. Jean Larochelle, as the physician in charge of local monitoring of children with tyrosinemia, "Quebec was the ideal place to conduct this research on tyrosinemia, since there were enough patients to draw valid scientific conclusions and the province enjoys close collaboration with the physicians in charge of monitoring and the group of parents of the affected children."

Study Details

To evaluate the efficacy of nitisinone, the researchers performed a retrospective examination of the course of the disease in patients in Quebec who had not received the treatment before 1994. They then compared their observations with the results of a prospective study of the course of the disease in patients who had been screened at birth starting in 1994. All of these patients were treated with nitisinone. Physicians from all of the university centers responsible for monitoring children with tyrosinemia in Quebec took part in the collaborative study. The children were monitored locally for their dietary and medical treatment and evaluated once a year at the Sainte-Justine UHC by a multidisciplinary team of medical specialists in genetics, liver diseases and medical imaging. The study was conducted in collaboration with patients who were members of a Quebec support group for children with tyrosinemia and their parents.

Despite the exciting conclusions, the researchers remain cautious. They stress the importance of continuing to monitor the development of complications related to tyrosinemia or the treatment itself. "We conducted this study over 25 years. It is long enough to be sure that nitisinone treatment definitely stops this liver disease or at least drastically slows down its progression," continues Dr. Mitchell. "This goes to show how some genetic diseases, even the most severe ones, are treatable," he concludes.


'/>"/>

Contact: William Raillant-Clark
w.raillant-clark@umontreal.ca
514-343-7593
University of Montreal
Source:Eurekalert

Related medicine news :

1. UGA researchers boost efficacy of drugs by using nanoparticles to target powerhouse of cells
2. RV144 vaccine efficacy increased against certain HIV viruses
3. Are there gender differences in anti-HIV drug efficacy?
4. New research confirms efficacy of transcranial magnetic stimulation for depression
5. Published clinical trial demonstrates efficacy of Sea-Band for migraine-related nausea
6. Efficacy of herbal remedies for managing insomnia
7. New delivery method improves efficacy of 2 common Parkinsons disease medications
8. Atrial fibrillation: Flec-SL trial proves efficacy of short-term antiarrhythmic drug treatment
9. Head-to-head study in RA shows that abatacept has comparable efficacy to adalimumab
10. Research shows efficacy of treatment model developed at Women & Infants
11. Legacy bead program helps children and their families cope with life-threatening illnesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... ... May 22, 2017 , ... WeightZone ... Wellocity to empower WeightZone Factor members to track their exercise patterns, monitor behavioral ... health education, all on their mobile phones. It also provides social networks for ...
(Date:5/21/2017)... ... May 20, 2017 , ... ... designs created specifically for use in Final Cut Pro X. The business-oriented elements ... productions. Pixel Film Studios’ ProParagraph Corporate will deliver a professional and distinguished look ...
(Date:5/21/2017)... ... , ... Following the tragic and widely publicized death of Rory Staunton, 12, ... hospitals follow a protocol to quickly identify and treat the condition. , The ... would have saved Rory or anyone else’s life. , Now, five years after ...
(Date:5/19/2017)... , ... May 19, 2017 , ... When Kyle Busch ... his name will already appear on two major research studies that could impact the ... with Dr. Matt Daggett, KCU alumnus and an orthopedic surgeon, alongside an international team ...
(Date:5/19/2017)... , ... May 19, 2017 , ... ... today announced a sponsorship and speaking session at the 7th Annual ET6 ... longest-running hosted enterprise mobility and digital transformation conference whose expressed purpose is to ...
Breaking Medicine News(10 mins):
(Date:5/8/2017)... , May 8, 2017 MACRA replaces ... from fee for service reimbursement. Black Book Research crowdsource-surveyed ... 1.       The Market for MIPS Compliance Technology ... of physician practices with 3 or more clinicians seek ... by Q4. "Given the magnitude of the changes, the ...
(Date:5/6/2017)... , May 5, 2017  May is Stroke Awareness ... of the most important methods to prevent a stroke: ... Centers for Disease Control and Prevention, undetected and uncontrolled ... Omron, the global leader in personal heart health ... elimination of heart attack and stroke and is advancing ...
(Date:5/4/2017)...  A recent study published in the American ... as a means of disinfection anesthesia workstations ... on anesthesia workstations. In the study, UVC disinfection ... equipment surfaces contaminated with three (3) organisms commonly ... further validates the body of literature supporting Tru-D," ...
Breaking Medicine Technology: